Atossa Genetics Inc (NASDAQ:ATOS) shares saw strong trading volume on Thursday . 1,562,028 shares were traded during mid-day trading, a decline of 19% from the previous session’s volume of 1,921,496 shares.The stock last traded at $2.27 and had previously closed at $2.24.
A number of analysts recently issued reports on the company. Maxim Group reissued a “hold” rating on shares of National Beverage in a research report on Thursday, June 27th. ValuEngine raised Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 27th.
The stock has a market capitalization of $21.40 million, a PE ratio of -0.41 and a beta of 3.31. The company’s 50-day moving average price is $2.32.
Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Monday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Atossa Genetics Inc will post -1.28 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Atossa Genetics stock. Barclays PLC acquired a new stake in shares of Atossa Genetics Inc (NASDAQ:ATOS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 32,384 shares of the company’s stock, valued at approximately $33,000. Barclays PLC owned about 0.57% of Atossa Genetics as of its most recent SEC filing. 3.18% of the stock is owned by institutional investors and hedge funds.
About Atossa Genetics (NASDAQ:ATOS)
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
See Also: Balance Sheet
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.